XML 59 R45.htm IDEA: XBRL DOCUMENT
v3.21.2

COMMITMENTS AND CONTINGENCIES (Details) - USD ($) |  |  |  |  |  |  | 3 Months Ended | 12 Months Ended |  |  |  |  |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Sep. 01, 2021 | May 07, 2020 | Sep. 30, 2017 | Nov. 30, 2016 | May 25, 2016 | Nov. 30, 2015 | Aug. 26, 2021 | May 31, 2021 | May 31, 2020 | Jun. 25, 2020 | May 28, 2020 | Dec. 31, 2019 | Sep. 25, 2019 | Jul. 22, 2019 | Jul. 12, 2019 | Jan. 31, 2018 | Nov. 30, 2017
COMMITMENTS AND CONTINGENCIES (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Expense |  |  |  |  |  |  |  | $ 2,410,506 | $ 1,910,209 |  |  |  |  |  |  |  |
Accrued Liabilities, Current |  |  |  |  |  |  |  | 151,759 | 153,299 |  |  |  |  |  |  |  |
University OF Southern California [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
COMMITMENTS AND CONTINGENCIES (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Clinical Trial Agreement Maximum Budgeted Costs |  |  | $ 82,472 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Expense |  |  | 12,567 |  |  |  |  |  | 2,200 |  |  |  |  |  |  |  |
Other Expenses |  |  | $ 14,767 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Accrued Liabilities, Current |  |  |  |  |  |  |  | 17,064 |  |  |  |  |  |  |  |  |
University OF Michigan [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
COMMITMENTS AND CONTINGENCIES (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Clinical Trial Agreement Maximum Budgeted Costs |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 181,015
Research and Development Expense |  |  |  |  |  |  |  | 20,550 | 30,900 |  |  |  |  |  |  |  |
Accrued Liabilities, Current |  |  |  |  |  |  |  | $ 2,050 |  |  |  |  |  |  |  |  |
Billed Commitment, Percentage |  |  |  |  |  |  |  | 56.00% |  |  |  |  |  |  |  |  |
University OF Beth Israel Deaconess Medical Center [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
COMMITMENTS AND CONTINGENCIES (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Clinical Trial Agreement Maximum Budgeted Costs |  |  |  |  |  |  |  | $ 305,000 |  |  |  |  |  |  |  | $ 142,000 |
Research and Development Expense |  |  |  |  |  |  |  | 0 | 141,640 |  |  |  |  |  |  |  |
Biomerica HP Stool Antigen [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
COMMITMENTS AND CONTINGENCIES (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Clinical Trial Agreement Maximum Budgeted Costs |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 117,200 |  |
Research and Development Expense |  |  |  |  |  |  |  | 13,111 | 13,355 |  |  |  |  |  |  |  |
Biomerica InFoods [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
COMMITMENTS AND CONTINGENCIES (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Clinical Trial Agreement Maximum Budgeted Costs |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 107,000 |  |  |
Research and Development Expense |  |  |  |  |  |  |  | 12,675 | 20,875 |  |  |  |  |  |  |  |
Accrued Liabilities, Current |  |  |  |  |  |  |  | $ 19,600 |  |  |  |  |  |  |  |  |
Billed Commitment, Percentage |  |  |  |  |  |  |  | 31.00% |  |  |  |  |  |  |  |  |
Medical Practice [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
COMMITMENTS AND CONTINGENCIES (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Clinical Trial Agreement Maximum Budgeted Costs |  |  |  |  |  |  |  |  |  |  |  |  | $ 136,000 |  |  |  |
Research and Development Expense |  |  |  |  |  |  |  | $ 11,725 | 45,250 |  |  |  |  |  |  |  |
Accrued Liabilities, Current |  |  |  |  |  |  |  |  | 5,975 |  |  |  |  |  |  |  |
Billed Commitment, Percentage |  |  |  |  |  |  |  | 42.00% |  |  |  |  |  |  |  |  |
Biomerica H. Pylori Product [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
COMMITMENTS AND CONTINGENCIES (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Clinical Trial Agreement Maximum Budgeted Costs |  |  |  |  |  |  |  |  |  |  |  |  | $ 57,800 |  |  |  |
Research and Development Expense |  |  |  |  |  |  |  |  | $ 41,845 |  |  |  |  |  |  |  |
Billed Commitment, Percentage |  |  |  |  |  |  |  |  | 72.00% |  |  |  |  |  |  |  |
Houseton Methodist Research Institute [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
COMMITMENTS AND CONTINGENCIES (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Clinical Trial Agreement Maximum Budgeted Costs |  |  |  |  |  |  |  |  |  |  |  | $ 133,000 |  |  |  |  |
Research and Development Expense |  |  |  |  |  |  |  | $ 0 | $ 4,000 |  |  |  |  |  |  |  |
Accrued Liabilities, Current |  |  |  |  |  |  |  | 3,550 |  |  |  |  |  |  |  |  |
Billed Commitment, Percentage |  |  |  |  |  |  |  |  | 3.00% |  |  |  |  |  |  |  |
Mayo Clinic Arizona [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
COMMITMENTS AND CONTINGENCIES (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Clinical Trial Agreement Maximum Budgeted Costs |  |  |  |  |  |  |  |  | $ 135,515 |  |  |  |  |  |  |  |
Research and Development Expense |  |  |  |  |  |  |  | 0 | 17,390 |  |  |  |  |  |  |  |
Accrued Liabilities, Current |  |  |  |  |  |  |  | $ 3,750 |  |  |  |  |  |  |  |  |
Billed Commitment, Percentage |  |  |  |  |  |  |  | 13.00% |  |  |  |  |  |  |  |  |
Mayo Clinic Jacksonville [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
COMMITMENTS AND CONTINGENCIES (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Clinical Trial Agreement Maximum Budgeted Costs |  |  |  |  |  |  |  |  |  |  | $ 135,515 |  |  |  |  |  |
Accrued Liabilities, Current |  |  |  |  |  |  |  |  | 17,390 |  |  |  |  |  |  |  |
Billed Commitment, Percentage |  |  |  |  |  |  |  | 17.00% |  |  |  |  |  |  |  |  |
Related Party Transaction, Amounts of Transaction |  |  |  |  |  |  |  | $ 22,827 |  |  |  |  |  |  |  |  |
University Of Texas Health Science Center [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
COMMITMENTS AND CONTINGENCIES (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Clinical Trial Agreement Maximum Budgeted Costs |  |  |  |  |  |  |  |  |  | $ 139,850 |  |  |  |  |  |  |
Research and Development Expense |  |  |  |  |  |  |  | 4,850 |  |  |  |  |  |  |  |  |
Accrued Liabilities, Current |  |  |  |  |  |  |  | $ 3,750 |  |  |  |  |  |  |  |  |
Billed Commitment, Percentage |  |  |  |  |  |  |  | 4.00% |  |  |  |  |  |  |  |  |
Royalty Agreements [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
COMMITMENTS AND CONTINGENCIES (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty Expense |  |  |  |  |  |  |  | $ 11,000 | 15,000 |  |  |  |  |  |  |  |
Telcon Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
COMMITMENTS AND CONTINGENCIES (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Accrued Fees and Other Revenue Receivable |  |  |  |  | $ 1,250,000 |  |  |  |  |  |  |  |  |  |  |  |
Stock Issued During Period, Shares, Other (in Shares) |  |  |  |  | 83,333 |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from Fees Received |  |  |  |  | $ 250,000 |  |  |  |  |  |  |  |  |  |  |  |
Royalty Percentage |  |  |  |  | 15.00% |  |  |  |  |  |  |  |  |  |  |  |
Mount Sinai License Agreements [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
COMMITMENTS AND CONTINGENCIES (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Related Party Transaction, Purchases from Related Party |  |  |  |  |  |  |  |  | $ 5,100 |  |  |  |  |  |  |  |
Mount Sinai License Agreements [Member] | Subsequent Event [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
COMMITMENTS AND CONTINGENCIES (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Related Party Transaction, Purchases from Related Party |  |  |  |  |  |  | $ 2,850 |  |  |  |  |  |  |  |  |  |
UC License Agreements [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
COMMITMENTS AND CONTINGENCIES (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payments for Other Fees |  | $ 5,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License Maintenance Fee, Payable |  | $ 10,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
UC License Agreements [Member] | Subsequent Event [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
COMMITMENTS AND CONTINGENCIES (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payments for Other Fees |  |  |  |  |  |  | $ 5,000 |  |  |  |  |  |  |  |  |  |
Building In Irvine California [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
COMMITMENTS AND CONTINGENCIES (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Operating Lease, Expense |  |  |  |  |  |  |  | $ 23,637 |  |  |  |  |  |  |  |  |
Building In Irvine California [Member] | Subsequent Event [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
COMMITMENTS AND CONTINGENCIES (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Rental Expense, Increase During Period | $ 25,970 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Rental Expense, Increase During The Period, Percentage | 3.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Lease Deposit Liability | $ 22,080 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Building In Irvine California [Member] | First Amendment To Lease [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
COMMITMENTS AND CONTINGENCIES (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Operating Leases Rent Expenses Minimum Rentals |  |  |  |  |  | $ 21,000 |  |  |  |  |  |  |  |  |  |  |
Rental Expense, Increase During Period |  |  |  |  |  | $ 23,637 |  |  |  |  |  |  |  |  |  |  |
Lease Expiration Date |  |  |  |  |  | Aug. 31, 2021 |  |  |  |  |  |  |  |  |  |  |
Revenue Benchmark [Member] | Royalty Agreements [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
COMMITMENTS AND CONTINGENCIES (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty Expense Percentage Of Sales |  |  |  |  |  |  |  | 1.50% | 1.80% |  |  |  |  |  |  |  |
MEXICO |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
COMMITMENTS AND CONTINGENCIES (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Operating Lease, Expense |  |  |  |  |  |  |  | $ 25,351 | $ 43,481 |  |  |  |  |  |  |  |
MEXICO | Property Available for Operating Lease [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
COMMITMENTS AND CONTINGENCIES (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Operating Leases Rent Expenses Minimum Rentals |  |  |  | $ 2,926 |  |  |  |  |  |  |  |  |  |  |  |  |
Operating Lease, Expense |  |  |  | $ 3,262 |  |  |  |  |  |  |  |  |  |  |  |  |
Lease Expiration Period |  |  |  | 10 years |  |  |  |  |  |  |  |  |  |  |  |  |
UNITED STATES |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
COMMITMENTS AND CONTINGENCIES (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Operating Lease, Expense |  |  |  |  |  |  |  | $ 294,759 | $ 300,267 |  |  |  |  |  |  |  |

X
- Definition Percentage of the commitment billed during the period. + References No definition available. + Details
Name: | bmra_BilledCommitmentPercentage
Namespace Prefix: | bmra_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems
Namespace Prefix: | bmra_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The maximum budgeted costs related to clinical trial agreement. + References No definition available. + Details
Name: | bmra_ClinicalTrialAgreementMaximumBudgetedCosts
Namespace Prefix: | bmra_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents the number of years in which the lease expires. + References No definition available. + Details
Name: | bmra_LeaseExpirationPeriod
Namespace Prefix: | bmra_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of license maintenance fee payable. + References No definition available. + Details
Name: | bmra_LicenseMaintenanceFeePayable
Namespace Prefix: | bmra_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition This element represents the payments that the lessee is obligated to make or can be required to make in connection with a property under the terms of an agreement classified as an operating lease, excluding contingent rentals and a guarantee by the lessee of the lessor's debt and the lessee's obligation to pay (apart from the rental payments) executory costs such as insurance, maintenance, and taxes. + References No definition available. + Details
Name: | bmra_OperatingLeasesRentExpensesMinimumRentals
Namespace Prefix: | bmra_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of rental expense increase during the period + References No definition available. + Details
Name: | bmra_RentalExpenseIncreaseDuringPeriod
Namespace Prefix: | bmra_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Percentage of rental expense increased during the period + References No definition available. + Details
Name: | bmra_RentalExpenseIncreaseDuringThePeriodPercentage
Namespace Prefix: | bmra_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Royalty expenses expressed as a percentage of sales. + References No definition available. + Details
Name: | bmra_RoyaltyExpensePercentageOfSales
Namespace Prefix: | bmra_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of royalty to be received. + References No definition available. + Details
Name: | bmra_RoyaltyPercentage
Namespace Prefix: | bmra_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition For an unclassified balance sheet, the amount of fees and other revenue, excluding investment income receivable, earned but not yet received, which were recognized in conformity with revenue recognition criteria based on estimates or specific contractual terms. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.3) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_AccruedFeesAndOtherRevenueReceivable
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_AccruedLiabilitiesCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of liability for lease payments received, including variable lease payments, when collectability is not probable at commencement date for sales-type lease. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 30 -Section 25 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=123408481&loc=SL77919106-209958 + Details
Name: | us-gaap_LeaseDepositLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Date which lease or group of leases is set to expire, in YYYY-MM-DD format. + References No definition available. + Details
Name: | us-gaap_LeaseExpirationDate1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:dateItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of operating lease expense. Excludes sublease income. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 45 -Paragraph 4 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977 + Details
Name: | us-gaap_OperatingLeaseExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of expense classified as other. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4,6) -URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.7) -URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263 + Details
Name: | us-gaap_OtherExpenses
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of cash outflow for fees classified as other. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (g) -URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585 + Details
Name: | us-gaap_PaymentsForFees
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Cash received for fees during the current period. This element excludes cash proceeds from license fees. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585 + Details
Name: | us-gaap_ProceedsFromFeesReceived
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of transactions with related party during the financial reporting period. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864 + Details
Name: | us-gaap_RelatedPartyTransactionAmountsOfTransaction
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party. + References No definition available. + Details
Name: | us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 912 -SubTopic 730 -Section 25 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.3) -URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227 + Details
Name: | us-gaap_RoyaltyExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of shares of stock issued attributable to transactions classified as other. + References No definition available. + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesOther
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_UniversityOFSouthernCaliforniaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_UniversityOFMichiganMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_UniversityOFBethIsraelDeaconessMedicalCenterMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_BiomericaHPStoolAntigenMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_BiomericaInFoodsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_MedicalPracticeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_BiomericaHPyloriProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_HousetonMethodistResearchInstituteMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_MayoClinicArizonaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_MayoClinicJacksonvilleMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_UniversityOfTexasHealthScienceCenterMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=us-gaap_RoyaltyAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=bmra_TelconAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=bmra_MountSinaiLicenseAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=bmra_UCLicenseAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=bmra_BuildingInIrvineCaliforniaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=bmra_FirstAmendmentToLeaseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_MX
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=us-gaap_PropertyAvailableForOperatingLeaseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |